Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
ADCETRIS (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
ADCETRIS
Date registered
Evaluation commenced
Decision date
Approval time
146 working days (255)
Active ingredients
brentuximab vedotin
Registration type
EOI
Indication
Peripheral T-cell lymphoma
ADCETRIS (powder for injection) is now also indicated for the treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) (see 5.1 Pharmacodynamic Propertues, Clinical Trials).